(852.3) Scleraxis is Required for Induction of GLS1 Expression in Cardiac Myofibroblasts

Poster Board Number: E67

Sikta Chattopadhyaya (Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre), Raghu Nagalingam (Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre), Pavit Narhan (Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre), Dayna Ledingham (Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre), Teri Moffatt (Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre), Michael Czubryt (Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre)

Cardiac fibrosis is an aberrant wound healing process involving excessive production of extracellular matrix proteins resulting in impaired systolic and diastolic function of the heart, contributing to heart failure and death. Glutaminolysis, which involves conversion of glutamine to glutamate by glutaminase (GLS), and conversion of glutamate to α-ketoglutarate to fuel oxidative metabolism via the tricarboxylic acid cycle, has been reported as a mechanism for meeting the energy demand required for pulmonary and liver fibrosis however its contribution in cardiac fibrosis is unclear. Although the role of the transcription factor Scleraxis has been established in the phenotypic conversion of cardiac fibroblasts to fibrotic myofibroblasts by our lab, Scleraxis’ role in glutaminolysis remains unelucidated. Our results here show Scleraxis expression was increased by 9 fold and GLS1 by 4 fold when comparing freshly isolated rat cardiac fibroblasts to fibrogenic myofibroblasts. While Scleraxis overexpression increased GLS1 expression 20-fold, Scleraxis knockdown attenuated GLS1 expression by 76% in cardiac myofibroblasts while cardiac fibroblasts from Scleraxis knockout mice exhibited a 90% loss of GLS1 expression. TGFβ, one of the primary inducers of cardiac fibrosis induces enhanced expression of Scleraxis and has been found to be highly dependent on Scleraxis for many of its downstream effects. TGFβ treatment of activated cardiac fibroblasts from wild type mice doubled the expression of GLS1, but failed to induce GLS1 expression in Scleraxis knockout cells. Via luciferase assay we found a dose-dependent transactivation of the human GLS1 promoter by Scleraxis in NIH3T3 fibroblasts. While Scleraxis significantly transactivated the hGLS1 promoter, mutation of an E-Box Scleraxis putative binding site caused 70% attenuation of promoter transactivation. These findings suggest that Scleraxis is sufficient and required to regulate GLS1 expression to facilitate increased energy metabolism during cardiac fibroblast to myofibroblast conversion.

Canadian Institutes of Health Research